291 related articles for article (PubMed ID: 30926528)
1. Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials.
Casula M; Olmastroni E; Boccalari MT; Tragni E; Pirillo A; Catapano AL
Pharmacol Res; 2019 May; 143():143-150. PubMed ID: 30926528
[TBL] [Abstract][Full Text] [Related]
2. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.
Navarese EP; Kolodziejczak M; Schulze V; Gurbel PA; Tantry U; Lin Y; Brockmeyer M; Kandzari DE; Kubica JM; D'Agostino RB; Kubica J; Volpe M; Agewall S; Kereiakes DJ; Kelm M
Ann Intern Med; 2015 Jul; 163(1):40-51. PubMed ID: 25915661
[TBL] [Abstract][Full Text] [Related]
3. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
[TBL] [Abstract][Full Text] [Related]
4. Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials.
Karatasakis A; Danek BA; Karacsonyi J; Rangan BV; Roesle MK; Knickelbine T; Miedema MD; Khalili H; Ahmad Z; Abdullah S; Banerjee S; Brilakis ES
J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29223954
[TBL] [Abstract][Full Text] [Related]
5. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R
Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202
[TBL] [Abstract][Full Text] [Related]
6. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.
Imran TF; Khan AA; Has P; Jacobson A; Bogin S; Khalid M; Khan A; Kim S; Erqou S; Choudhary G; Aspry K; Wu WC
PLoS One; 2023; 18(12):e0295359. PubMed ID: 38055686
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials.
Kereiakes DJ; Lepor NE; Gerber R; Veronica Lee L; Elassal J; Thompson D; Michael Gibson C
Atherosclerosis; 2018 Oct; 277():211-218. PubMed ID: 30025648
[TBL] [Abstract][Full Text] [Related]
8. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS
JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070
[TBL] [Abstract][Full Text] [Related]
9. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.
Li C; Lin L; Zhang W; Zhou L; Wang H; Luo X; Luo H; Cai Y; Zeng C
J Am Heart Assoc; 2015 Jun; 4(6):e001937. PubMed ID: 26077586
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials.
Mu G; Xiang Q; Zhou S; Liu Z; Qi L; Jiang J; Gong Y; Xie Q; Wang Z; Zhang H; Huo Y; Cui Y
Adv Ther; 2020 Apr; 37(4):1496-1521. PubMed ID: 32108309
[TBL] [Abstract][Full Text] [Related]
11. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk.
Milionis H; Barkas F; Ntaios G; Papavasileiou V; Vemmos K; Michel P; Elisaf M
Eur J Intern Med; 2016 Oct; 34():54-57. PubMed ID: 27363304
[TBL] [Abstract][Full Text] [Related]
12. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
13. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of randomized clinical trials comparing PCSK9 monoclonal antibody versus ezetimibe/placebo in patients at high cardiovascular risk.
Ma W; Guo X; Ma Y; Hu Z
Atherosclerosis; 2021 Jun; 326():25-34. PubMed ID: 34004550
[TBL] [Abstract][Full Text] [Related]
15. The Role of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia.
Patel RS; Scopelliti EM; Olugbile O
Ann Pharmacother; 2018 Oct; 52(10):1000-1018. PubMed ID: 29667842
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY OUTCOMES Trial.
Turgeon RD; Tsuyuki RT; Gyenes GT; Pearson GJ
Can J Cardiol; 2018 Dec; 34(12):1600-1605. PubMed ID: 30527147
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
Sabatine MS; Leiter LA; Wiviott SD; Giugliano RP; Deedwania P; De Ferrari GM; Murphy SA; Kuder JF; Gouni-Berthold I; Lewis BS; Handelsman Y; Pineda AL; Honarpour N; Keech AC; Sever PS; Pedersen TR
Lancet Diabetes Endocrinol; 2017 Dec; 5(12):941-950. PubMed ID: 28927706
[TBL] [Abstract][Full Text] [Related]
18. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Schwartz GG; Bessac L; Berdan LG; Bhatt DL; Bittner V; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Mahaffey KW; Moryusef A; Pordy R; Roe MT; Rorick T; Sasiela WJ; Shirodaria C; Szarek M; Tamby JF; Tricoci P; White H; Zeiher A; Steg PG
Am Heart J; 2014 Nov; 168(5):682-9. PubMed ID: 25440796
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials.
Zhang XL; Zhu QQ; Zhu L; Chen JZ; Chen QH; Li GN; Xie J; Kang LN; Xu B
BMC Med; 2015 Jun; 13():123. PubMed ID: 26099511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
